HC Wainwright Raises Celldex Therapeutics (NASDAQ:CLDX) Price Target to $80.00

Celldex Therapeutics (NASDAQ:CLDX) had its target price lifted by HC Wainwright from $73.00 to $80.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald cut their price objective on Celldex Therapeutics from $54.00 to $52.00 and set an overweight rating on the stock in a report on Friday. Wells Fargo & Company began coverage on Celldex Therapeutics in a report on Tuesday, August 22nd. They set an underweight rating on the stock. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of Hold and an average target price of $65.00.

Celldex Therapeutics Trading Up 13.0 %

Shares of Celldex Therapeutics stock opened at $29.35 on Monday. The company’s 50-day moving average price is $26.48 and its two-hundred day moving average price is $31.17. Celldex Therapeutics has a 52 week low of $22.11 and a 52 week high of $48.40. The stock has a market cap of $1.39 billion, a PE ratio of -11.12 and a beta of 2.06.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.67 million. Celldex Therapeutics had a negative return on equity of 36.15% and a negative net margin of 3,475.70%. On average, equities analysts predict that Celldex Therapeutics will post -2.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP grew its stake in shares of Celldex Therapeutics by 61.5% in the 1st quarter. Wellington Management Group LLP now owns 3,529,840 shares of the biopharmaceutical company’s stock valued at $120,227,000 after buying an additional 1,343,864 shares in the last quarter. BlackRock Inc. grew its stake in shares of Celldex Therapeutics by 0.8% in the 1st quarter. BlackRock Inc. now owns 3,250,638 shares of the biopharmaceutical company’s stock valued at $116,958,000 after buying an additional 25,922 shares in the last quarter. State Street Corp grew its stake in shares of Celldex Therapeutics by 20.4% in the 2nd quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock valued at $87,050,000 after buying an additional 546,124 shares in the last quarter. Kynam Capital Management LP grew its stake in shares of Celldex Therapeutics by 84.5% in the 2nd quarter. Kynam Capital Management LP now owns 2,600,000 shares of the biopharmaceutical company’s stock valued at $88,218,000 after buying an additional 1,190,549 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Celldex Therapeutics by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,475,381 shares of the biopharmaceutical company’s stock valued at $69,583,000 after buying an additional 40,009 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.